Form 4 for PCVX Vaxcyte, Inc.
Accepted 2024-04-03 00:00:00 ET · period of report 2024-04-01 · accession 0001415889-24-010000 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-04-03 | 2024-04-01 | PCVX | Wassil Jim | COO | S - Sale | $66.69 | -3,000 | 218.3K | -1% | -$200.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-01 | S | D | 2,323 | $66.53 | 218,966 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $66.09 to $67.07. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2024-04-01 | S | D | 677 | $67.23 | 218,289 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $67.13 to $68.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |